• Partnership to focus on implementing a medical product development strategy for VIVO’s global medical cannabis offering, utilizing CB2 Insights’ leading technology platform Sail and research capabilities
  • Joint venture will aim to increase the collection of real word data to assist health care stakeholders in making informed decisions on new cannabis-based treatments for patients
  • In collaboration, VIVO and CB2 Insights will look to uncover data trends and insights from Canada that will help inform ventures in the international marketplace

TORONTO, Oct. 29, 2019 (GLOBE NEWSWIRE) — CB2 Insights Inc. (CSE:CBII; OTCQB: CBIIF) (“CB2”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announced it has entered into a technology and multi-phase research agreement with VIVO Cannabis Inc. (TSX-V: VIVO, OTCQX: VVCIF) (“VIVO”), an Ontario-based cannabis company recognized for its premium products and services, to assist in the development of VIVO’s global medical product development strategy.

Under the terms of the agreement, CB2 will be integrating CB2’s Clinical Data Management Software (CDMS) and Electronic Data Capture (EDC) tools to establish better understanding of VIVO’s current medical patient registry. Concurrently, the two companies will collaborate on a comprehensive multi-phase research strategy that will validate the safety and efficacy of current products. The plan is ultimately expected to help inform the design of clinical trials to support the deployment of future cannabis-based medicines.

“As the industry continues to evolve, regulatory bodies are putting greater emphasis on the validation of cannabis-based treatments through clinical trial data to measure their safety and efficacy,” said Prad Sekar, CEO of CB2. “ We will work closely with the team at VIVO to design a research strategy backed by the collection of high-quality real world clinical data to support their current and future product innovations.”

“CB2’s global experience in clinical research and technology will enable VIVO to enhance our understanding of Canadian medical patients. This will facilitate our uncovering of new ways to meet the expectations of our current patients and will help inform our international growth plans,” said Barry Fishman, CEO of VIVO. “At VIVO, our purpose is to help patients achieve a positive quality of life with cannabis. We look forward to utilizing our partnership with CB2 to further bring real world evidence to the medical cannabis industry.”

Skylight Health

Author Skylight Health

More posts by Skylight Health

Leave a Reply